COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Maryam Sharifian-Dorche, Mohammad Ali Sahraian, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Maryam Karaminia, Alexander William Saveriano, Roberta La Piana, Jack P. Antel, Paul Steven Giacomini

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: The Coronavirus disease-19 (COVID-19) pandemic continues to expand across the world. This pandemic has had a significant impact on patients with chronic diseases. Among patients with demyelinating diseases of the central nervous system (CNS), such as Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD), concerns remain about the potential impact of COVID-19 on these patients given their treatment with immunosuppressive or immunomodulatory therapies. In this study, we review the existing literature investigating the impact of disease-modifying therapies(DMT) on COVID-19 risks in this group of patients. Method: For this systematic review, we searched PubMed from January 1, 2020, to December 3, 2020. The following keywords were used: “COVID-19” AND “Multiple Sclerosis” OR “Neuromyelitis Optica.” Articles evaluating COVID-19 in patients with demyelinating diseases of CNS were included. This study evaluates the different aspects of the DMTs in these patients during the COVID-19 era. Results and conclusion: A total of 262 articles were found. After eliminating duplicates and unrelated research papers, a total of 84 articles met the final inclusion criteria in our study. Overall, the experiences of 2493 MS patients and 37 NMOSD patients with COVID-19 were included in this review. Among them, 46(1.8%) MS patients died(the global death-to-case ratio of Covid-19 was reported about 2.1%). Among DMTs, Rituximab had the highest mortality rate (4%). Despite controversies, especially concerning anti-CD20 monoclonal antibody therapies, a relation between DMT-use and COVID-19 disease- course was not found in many studies. This observation reinforces the recommendation of not stopping current DMTs. Other variables such as age, higher expanded disability status scale (EDSS) scores, cardiac comorbidities, and obesity were independent risk factors for severe COVID-19. Despite the risks of infection, most patients were willing to continue their DMT during the pandemic because of more significant concern about the risk of relapse or worsening MS symptoms. After the infection, an immune response's attenuation was seen in the patients on Fingolimod and anti-CD20 monoclonal antibodies. This may be a critical finding in future vaccinations.

Original languageEnglish
Article number102800
JournalMultiple Sclerosis and Related Disorders
Volume50
DOIs
Publication statusPublished - May 2021
Externally publishedYes

Keywords

  • COVID-19
  • Disease-modifying therapies
  • Multiple sclerosis
  • Neuromyelitis optica spectrum disorder

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review'. Together they form a unique fingerprint.

Cite this